Literature DB >> 3160067

Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.

E D Wigle, Z Sasson, M A Henderson, T D Ruddy, J Fulop, H Rakowski, W G Williams.   

Abstract

Hypertrophic cardiomyopathy is a diverse clinical and pathophysiologic entity that involves principally the left ventricle and is caused by asymmetric or concentric hypertrophy of unknown cause. If asymmetric, the hypertrophy is usually greatest in the ventricular septum, but variations occur in which the hypertrophy may be maximal at the apex, at the midventricular level, or, rarely, in the free wall of the left ventricle. Right ventricular involvement is usually less evident. The principal abnormality in systole is the obstruction to left ventricular outflow caused by upper septal hypertrophy narrowing the outflow tract and setting the stage for Venturi forces to cause systolic anterior motion of the anterior or posterior mitral leaflets. The time of onset and duration of mitral leaflet-septal contact determine the magnitude of the pressure gradient. Mitral regurgitation invariably accompanies the obstruction to outflow. Ventriculomyotomy-myectomy surgery, by thinning the septum and widening the outflow tract, abolishes the abnormal mitral leaflet motion and, consequently, the obstruction to outflow and the mitral regurgitation. This form of surgery more dramatically relieves the systolic abnormalities and the accompanying symptoms than any form of medical therapy available today. The extent of hypertrophy is believed to be the principal determinant of the impaired left ventricular relaxation and increased chambers stiffness (decreased compliance) that characterize diastole in hypertrophic cardiomyopathy. Relaxation is impaired by the contraction load (the obstruction), by a decrease in the principal relaxation loads, by a pathologic degree of nonuniformity of contraction and relaxation, and in all likelihood, by impaired inactivation of the biochemical processes responsible for contraction (? due to primary or ischemia-induced calcium overload). Calcium channel-blocking agents may dramatically improve left ventricular relaxation by speeding up the inactivation process, by decreasing the degree of nonuniformity, or by altering the contraction and relaxation loads in a favorable manner. Atrial and ventricular arrhythmias are responsible for a significant proportion of the morbidity and mortality, and their occurrence also appears to depend on the extent of hypertrophy. Thus, the major manifestations of hypertrophic cardiomyopathy in systole and diastole as well as the disturbances of rhythm appear to be related to the site and/or extent of the hypertrophic process.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1985        PMID: 3160067     DOI: 10.1016/0033-0620(85)90024-6

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  85 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: comparison with normal subjects.

Authors:  Quirino Ciampi; Sandro Betocchi; Anna Violante; Raffaella Lombardi; Maria Angela Losi; Giovanni Storto; Fiore Manganelli; Carlo Gabriele Tocchetti; Mariano Aversa; Elpidio Pezzella; Filippo Finizio; Alberto Cuocolo; Massimo Chiariello
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

3.  HLA gene analysis in a Japanese family with hypertrophic cardiomyopathy by restriction fragment length polymorphism.

Authors:  T Kanda; N Takeuchi; A Hasegawa; T Suzuki; K Murata
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

4.  Ventricular dysfunction in hypertrophic obstructive cardiomyopathy.

Authors:  R D Leachman
Journal:  Tex Heart Inst J       Date:  1991

5.  No evidence for linkage of familial hypertrophic cardiomyopathy and chromosome 14q1 locus D14S26 in a Chinese family: evidence for genetic heterogeneity.

Authors:  Y L Ko; W P Lien; J J Chen; C W Wu; T K Tang; C C Liew
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

6.  Acquired cardiac hypertrophy with outflow tract obstruction in a patient with severe Takayasu arteritis.

Authors:  Senay Funda Biyikoglu; Meltem Ege; Mehmet Birhan Yilmaz; Erdal Duru; Ali Sasmaz
Journal:  Int J Cardiovasc Imaging       Date:  2006-06-29       Impact factor: 2.357

7.  Endogenous endothelin 1 mediates angiotensin II-induced hypertrophy in electrically paced cardiac myocytes through EGFR transactivation, reactive oxygen species and NHE-1.

Authors:  María V Correa; Mariela B Nolly; Claudia I Caldiz; Gladys E Chiappe de Cingolani; Horacio E Cingolani; Irene L Ennis
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

8.  Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis.

Authors:  A Woo; H Rakowski; J C Liew; M-S Zhao; C-C Liew; T G Parker; M Zeller; E D Wigle; M J Sole
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

9.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 10.  Athlete's heart or hypertrophic cardiomyopathy?

Authors:  Jörg Lauschke; Bernhard Maisch
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.